The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Blood Biomarker Discovery For The Diagnosis Of Alzheimers Disease
Funder
National Health and Medical Research Council
Funding Amount
$292,639.00
Summary
Alzheimer's disease (AD) currently affects approximately 24 million people world wide, with >200,000 people within Australia currently affected, by 2050 an estimated 730,000+ people will be affected. The discovery of blood based biomarkers for AD will enable earlier diagnosis of AD, allowing early preventative treatments to be given. Thus, reduce the rate of disease progression and the cost of care and, gain significant improvement in the quality of life for the patients and their families.
Targeting The Metastasis Suppressor NDRG1 For The Treatment Of Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$327,142.00
Summary
We will investigate NDRG1, a novel molecular target that has been demonstrated to inhibit the progression of numerous cancers. We aim to better understand the underlying functions of NDRG1 in pancreatic cancer and how we can potentially target this gene with novel therapeutics being developed in our laboratory. We hope that this new approach will lead to more promising treatment options and a better outcome for those suffering from pancreatic cancer.
Studying The Function And Mechanism Of Histone ADP-ribosylation; (ii) Lipo-peptide--protein Vaccine Development
Funder
National Health and Medical Research Council
Funding Amount
$496,076.00
Summary
(i) Histones, which act as DNA supports, are subject to modifications, which may be associated with disease (e.g. cancers). A better understanding of these modifications will provide access to new medicines (ii) The production of new vaccines requires new vaccine development tools. We propose to use fats to produce vaccines which can be delivered via the mouth or nose rather than by injection.
TARGETING THE CHK1-STAT3-CIP2A AXIS TO TREAT GLIOBLASTOMA (GBM)
Funder
National Health and Medical Research Council
Funding Amount
$321,048.00
Summary
Glioblastoma (GBM is a high-grade brain tumour for which current treatments are inadequate. Tumour recurrence is almost inevitable and average life expectancy is measured in months. We have identified a DNA-damage signalling pathway and demonstrated that perturbation of the pathway significantly reduces tumour growth. We plan to target key proteins of the recently identified pathway and validate these findings using tumour cells directly from GBM patients and relevant animal models of human GBM.
CHARACTERISING FACIAL EMOTION PROCESSING NETWORKS IN BIPOLAR DISORDER
Funder
National Health and Medical Research Council
Funding Amount
$339,188.00
Summary
This research will use cutting edge imaging methodologies to investigate brain connectivity in neural circuits involved in emotion processing in people with bipolar disorder compared to their relatives and controls. It will provide insight into the factors associated with disease expression and genetic risk and will directly inform novel cognitive remediation treatments focused on directly addressing emotional processing difficulties in bipolar disorder at their source.
Development Of Prognostic And Predictive Biomarkers To Aid Treatment Of Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$188,226.00
Summary
Although a number of new therapies are emerging in the treatment of lung cancer, chemotherapy remains the backbone of treatment for most patients. Currently we are unable to predict who will benefit from chemotherapy with some patients deriving no benefit but experiencing significant toxicity. Our group has investigated a number of biomarkers and found them to predict response to chemotherapy. These markers may be used to determine patients most likely to derive benefit from chemotherapy.
Identifying Novel Genome Instability Signatures In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
Cancer is the single biggest clinical problem facing the world. An underlying hallmark of cancer is the accumulation of errors in the genetic information of a cell which arises through genomic instability. This research project aims to investigate novel molecules identified by our screening that function in response to genomic instability in cancer. This study is expected to define roles for each molecule in the maintenance of genomic stability and predict for patient diagnosis and outcome.
Objectively Monitoring Neurodegenerative Disease Progression: Speech As A Clinical Marker
Funder
National Health and Medical Research Council
Funding Amount
$302,123.00
Summary
It is difficult to monitor disease progression in some neurodegenerative disorders like Huntington’s disease or types of dementia without using expensive and invasive assessment techniques. Yet, by repeatedly recording and analysing the speech (how we speak, not what we say) of a patient, we build up a picture of how the brain is functioning and changing over time. This will lead to a more personalized approach with more effective treatments being given to the right patients at the right time.